GlassScriptPhysician profile
Gina Matacia
NPI 1891906459
$4,640.60
in general payments reported to CMS, 2019-2025
29 companies · $338 in 2025
The $338 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.50 · 2020: $74.34 · 2021: $261 · 2022: $384 · 2023: $3,318 · 2024: $211 · 2025: $338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,660 · Food and Beverage: $1,182 · Travel and Lodging: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,660.00 |
| Food and Beverage | $1,181.70 |
| Travel and Lodging | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $3,276.24 | 2019-2023 | Lynparza, Keytruda |
| Lilly USA, LLC | $153.01 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Novartis Pharmaceuticals Corporation | $144.85 | 2019-2025 | |
| Incyte Corporation | $121.12 | 2021 | |
| Pfizer INC. | $114.59 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $92.77 | 2023-2025 | Calquence, Enhertu |
| Daiichi Sankyo INC. | $82.07 | 2020-2025 | Injectafer, Enhertu |
| Abbvie INC. | $65.00 | 2024-2025 | |
| Amgen INC. | $64.78 | 2019-2022 | |
| Celgene Corporation | $60.27 | 2023 | Reblozyl, Pomalyst |
| Glaxosmithkline, LLC. | $57.48 | 2022-2024 | Ojjaara |
| Gilead Sciences, INC. | $52.68 | 2025 | Trodelvy |
| Aveo Pharmaceuticals, INC. | $42.30 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $35.81 | 2021-2022 | |
| Rigel Pharmaceuticals, INC. | $26.75 | 2024 | Rezlidhia, Tavalisse |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $24.51 | 2023 | Sancuso |
| Eisai INC. | $20.83 | 2022 | |
| Alexion Pharmaceuticals, INC. | $20.38 | 2024 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $19.61 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.60 | 2022 | |
| Stemline Therapeutics INC. | $18.10 | 2023 | Orserdu |
| Emd Serono, INC. | $17.32 | 2023 | Tepmetko |
| Taiho Oncology, INC. | $17.31 | 2023 | |
| Novo Nordisk INC | $17.00 | 2023 | Novoeight, Rebinyn |
| Genzyme Corporation | $16.30 | 2025 | |
| Puma Biotechnology, INC. | $15.82 | 2023 | |
| Deciphera Pharmaceuticals INC. | $14.88 | 2023 | Qinlock |
| Astellas Pharma US INC | $14.82 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $14.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gina Matacia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.